Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection

Elena Kuzmanova, Marilena Spanou, Emma Leckie, Nikolai Zhelev

    Research output: Contribution to journalMeeting Abstract

    Abstract

    Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.
    Original languageEnglish
    Number of pages1
    JournalBioDiscovery
    DOIs
    Publication statusPublished - 5 Jul 2017
    EventWorld Biodiscovery Congress 2017 - The Sofia University, Sofia, Bulgaria
    Duration: 17 Jul 201719 Jul 2017
    http://www.biodiscoverycongress.com/

    Fingerprint

    Thymidine Kinase
    High Pressure Liquid Chromatography
    Breast Neoplasms
    Serum
    Tumor Biomarkers
    Isotopes
    Biomarkers
    Antibodies
    Neoplasms
    Therapeutics

    Cite this

    Kuzmanova, Elena ; Spanou, Marilena ; Leckie, Emma ; Zhelev, Nikolai. / Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection. In: BioDiscovery. 2017.
    @article{3a2b08a03d6349a9a120f14c47e6d297,
    title = "Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection",
    abstract = "Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.",
    author = "Elena Kuzmanova and Marilena Spanou and Emma Leckie and Nikolai Zhelev",
    year = "2017",
    month = "7",
    day = "5",
    doi = "10.3897/biodiscovery.20.e14563",
    language = "English",
    journal = "BioDiscovery",
    issn = "2050-2966",

    }

    Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection. / Kuzmanova, Elena; Spanou, Marilena; Leckie, Emma; Zhelev, Nikolai.

    In: BioDiscovery, 05.07.2017.

    Research output: Contribution to journalMeeting Abstract

    TY - JOUR

    T1 - Validation of a novel HPLC-based serum thymidine kinase assay for breast cancer detection

    AU - Kuzmanova, Elena

    AU - Spanou, Marilena

    AU - Leckie, Emma

    AU - Zhelev, Nikolai

    PY - 2017/7/5

    Y1 - 2017/7/5

    N2 - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.

    AB - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring TK activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. In addition, it has comparable sensitivity with the radioenzymatic assay used in the clinical practice. The assay has been evaluated with samples from breast cancer patients.

    U2 - 10.3897/biodiscovery.20.e14563

    DO - 10.3897/biodiscovery.20.e14563

    M3 - Meeting Abstract

    JO - BioDiscovery

    JF - BioDiscovery

    SN - 2050-2966

    ER -